The burden of illness associated with hepatocellular carcinoma in the United States

Journal of Hepatology

Volumn 50, Issue 1, 2009, Pages 89-99

  Lang, Kathleen ^a   Danchenko, Natalya ^a   Gondek, Kathleen ^b   Shah, Sonalee ^b   Thompson, David ^a  

^a i3 Global   (Canada)

^b BAYER CORPORATION   (United States)

Author keywords

Burden of illness; Cost of illness; Hepatocellular carcinoma (HCC); Outcomes; Prevalence; Treatment pattern

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MALE; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; COST OF ILLNESS; EFFICIENCY; FEMALE; HEALTH CARE COSTS; HUMANS; LIVER NEOPLASMS; MALE; MEDICARE; MIDDLE AGED; PREVALENCE; SEER PROGRAM; UNITED STATES; YOUNG ADULT;

EID: 56949104495     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.07.029     Document Type: Article

References (49)

1. McGlynn K.A., Tarone R.E., and El-Serag H.B. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 15 (2006) 1198-1203
2. Erhardt A., Theobald I., Petry W., Röhrborn A., Heintges T., Wettstein M., et al. Hepatocellular carcinoma. Dtsch Med Wochenschr 127 (2002) 2665-2668
3. Verhoef C., Holman F.A., de Man R.A., de Wilt J.H.W., and Ijzermans J.N.M. Resection of extrahepatic hepatocellular carcinoma metastasis can result in long-term survival. Acta Chir Belg 105 (2005) 533-536
4. Bruix J., and Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
5. Bayer Corporate Web site. Investor News 2004: Bayer and Onyx Announce Phase II Results of Treatment with BAY 43-9006 in patients with advanced primary liver cancer. Available from: [accessed July 2008].
6. Wild C.P., and Hall A.J. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 462 (2000) 381-393
7. Stuver S.O. Towards global control of liver cancer?. Semin Cancer Biol 8 (1998) 299-306
8. Laurent C., Blanc F., Nobili S., Sa Cunha A., le Bail B., Bioulac-Sage P., et al. Prognostic factors and long-term survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. J Am Coll Surg 201 (2005) 656-662
9. Llovet J.M., Di Bisceglie A.M., Bruix J., Kramer B.S., Lencioni R., Zhu A.X., et al. Panel of experts in HCC design clinical trials design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100 (2008) 698-711
10. El-Serag H.B. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36 (2002) S74-S83
11. Rizzetto M. Hepatocellular carcinoma: screening and therapy. Minerva Gastroenterol Dietol 46 (2000) 143-147
12. Taketomi A., Soejima Y., Yoshizumi T., Uchiyama H., Yamashita Y., and Maehara Y. Liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 15 (2008) 124-130
13. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003) 429-442
14. Llovet J., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
15. FDA. Center for Drug Evaluation and Research. Press release: FDA Approves Sorafenib (Nexavar) for the Treatment of Unresectable Hepatocellular Carcinoma. November 20, 2007. Available from: [accessed July 2008].
16. Patel D., Terrault N.A., Yao F.Y., Bass N.M., and Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 3 (2005) 75-84
17. Ruelas-Villavicencio A.L., and Vargas-Vorácková F. In whom, how and how often is surveillance for hepatocellular carcinoma cost-effective?. Ann Hepatol 3 (2004) 152-159
18. Lin O.S., Keeffe E.B., Sanders G.D., and Owens D.K. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 19 (2004) 1159-1172
19. Arguedas M.R., Chen V.K., Eloubeidi M.A., and Fallon M.B. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 98 (2003) 679-690
20. Yuen M.-F., and Lai C.-L. Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. Ann Oncol 14 (2003) 1463-1467
21. Wong J.B. Cost-effectiveness of treatments for chronic hepatitis C. Am J Med 107 (1999) 74S-78S
22. Sarasin F.P., Majno P.E., Llovet J.M., Bruix J., Mentha G., and Hadenque A. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. Hepatology 33 (2001) 1073-1079
23. Seror O., N'Kontchou G., Tin Tin Htar M., Durand-Zaleski I., Trinchet J.C., Sellier N., et al. Ethanol versus radiofrequency ablation for the treatment of small hepatocellular carcinoma in patients with cirrhosis: a retrospective study of efficacy and cost. Gastroenterol Clin Biol 30 (2006) 1265-1273
24. Ikeda K., Kobayashi M., Saitoh S., Someya T., Hosaka T., Sezaki H., et al. Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3 cm or less in diameter. Hepatol Res 33 (2005) 241-249
25. Wilson L.S., and Lightwood J.M. Pancreatic cancer: total costs and utilization of health services. J Surg Oncol 71 (1999) 171-181
26. Chang S., Long S.R., Kutikova L., Bowman L., Finley D., Crown W.H., et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 22 (2004) 3524-3530
27. Kim W.R., Gores G.J., Benson J.T., Therneau R.M., and Melton L.J. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology 129 (2005) 486-493
28. Sloane D., Chen H., and Howell C. Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc 98 (2006) 1934-1939
29. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 13 Regs Public-Use, Nov 2004 Sub (1973-2002 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission.
30. Wang X., Hershman D.L., Abrams J.A., Feingold D., Grann V.R., Jacobson J.S., et al. Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer 97 (2007) 1606-1612
31. Brown M.L., Riley G.F., Schussler N., and Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 40 (2002) IV104-IV117
32. Berger A., Smith M., Lidsky L., Seifeldin R., and Oster G. Opioid use and health-care charges at the end of life in patients with metastatic cancer. Manag Care Interface 17 (2004) 28-34
33. RxList. Zofran indications and usage, dosage and administration. Available from: [accessed July 2008].
34. Fisch M., Callahan C.M., Kesterson J.G., Nichols C., and Tierney W.M. The use of an electronic patient record system to identify advanced cancer patients and antidepressant drug use. J Palliat Med 2 (1999) 403-409
35. Jazieh A.R., Kopp M., Foraida M., Ghouse M., Khalil M., Savidge M., et al. The use of dietary supplements by veterans with cancer. J Altern Complement Med 10 (2004) 560-564
36. Best J.H., Veenstra D.L., and Geppert J. Trends in expenditures for Medicare liver transplant recipients. Liver Transpl 7 (2001) 858-862
37. Fernandez J.A., Robles R., Marin C., Sánchez-Bueno F., Ramirez P., Pons J.A., et al. Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size?. Transplant Proc 35 (2003) 1818-1820
38. Yao F.Y., Ferrell L., Bass N.M., Watson J.J., Bacchetti P., Venook A., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33 (2001) 1394-1403
39. Easton Associates Interviews and Analysis. Unpublished data collected by Easton Associates, LLC, 2004.
40. Evans R.W., Manninen D.L., and Dong F.B. An economic analysis of liver transplantation. Costs, insurance coverage, and reimbursement. Gastroenterol Clin North Am 22 (1993) 451-473
41. Drug Topics. Red book. Montvale (NJ): Medical Economics; 2004.
42. Yabroff K.R., Lawrence W.F., Clauser S., Davis W.W., and Brown M.L. Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst 96 (2004) 1322-1330
43. US Bureau of Labor Statistics. Median usual weekly earnings of full-time wage and salary workers. Available from: [accessed July 2008].
44. Rice DP. Estimating the cost of illness. Health Economics Series, No. 6, DHEW Pub No. (PHS) 947-6. Rockville (MD): U.S. Department of Health Education and Welfare; 1966.
45. Krahn M.D., Mahoney J.E., Eckman M.H., Trachtenberg J., Pauker S.G., and Detsky A.S. Screening for prostate cancer. A decision analytic view. JAMA 272 (1994) 773-780
46. Taplin S.H., Barlow W., Urban N., Mandelson M.T., Timlin D.J., Ichikawa L., et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 87 (1995) 417-426
47. But D.Y., Lai C.L., and Yuen M.F. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 14 (2008) 1652-1656
48. Du X., Freeman J.L., and Goodwin J.S. Information on radiation treatment in patients with breast cancer: the advantages of the linked Medicare and SEER data. J Clin Epidemiol 52 (1999) 463-470
49. National Cancer Institute. SEER-Medicare Publications, 2005. Available from: [accessed October 2007].